留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

含去甲氧柔红霉素的预处理方案在异基因造血干细胞移植治疗高危难治性白血病中的疗效分析

程昊钰 杨怡欣 杨帆 张维婕 费新红 殷宇明 顾江英 满其航 赵杰 王静波

程昊钰, 杨怡欣, 杨帆, 等. 含去甲氧柔红霉素的预处理方案在异基因造血干细胞移植治疗高危难治性白血病中的疗效分析[J]. 器官移植, 2020, 11(2): 240-246. doi: 10.3969/j.issn.1674-7445.2020.02.009
引用本文: 程昊钰, 杨怡欣, 杨帆, 等. 含去甲氧柔红霉素的预处理方案在异基因造血干细胞移植治疗高危难治性白血病中的疗效分析[J]. 器官移植, 2020, 11(2): 240-246. doi: 10.3969/j.issn.1674-7445.2020.02.009
Cheng Haoyu, Yang Yixin, Yang Fan, et al. Analysis of the efficacy of pretreatment regimen containing idarubicin in allogeneic hematopoietic stem cell transplantation for high-risk refractory leukemia[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 240-246. doi: 10.3969/j.issn.1674-7445.2020.02.009
Citation: Cheng Haoyu, Yang Yixin, Yang Fan, et al. Analysis of the efficacy of pretreatment regimen containing idarubicin in allogeneic hematopoietic stem cell transplantation for high-risk refractory leukemia[J]. ORGAN TRANSPLANTATION, 2020, 11(2): 240-246. doi: 10.3969/j.issn.1674-7445.2020.02.009

含去甲氧柔红霉素的预处理方案在异基因造血干细胞移植治疗高危难治性白血病中的疗效分析

doi: 10.3969/j.issn.1674-7445.2020.02.009
基金项目: 

首都临床特色应用研究与成果推广 Z171100001017103

详细信息
    作者简介:

    程昊钰,女,1978年生,硕士,主治医师,研究方向为造血干细胞移植及其合并症的诊治,Email:chyky6778@hotmail.com

    通讯作者:

    王静波,女,1966年生,博士,主任医师,研究方向为造血干细胞移植治疗血液系统疾病,Email:dpwangjingbo@vip.sina.com

  • 中图分类号: R617, R733.7

Analysis of the efficacy of pretreatment regimen containing idarubicin in allogeneic hematopoietic stem cell transplantation for high-risk refractory leukemia

More Information
  • 摘要:   目的  探讨含去甲氧柔红霉素(IDA)的预处理方案在异基因造血干细胞移植(allo-HSCT)治疗高危难治性白血病中的临床疗效。  方法  对116例接受了allo-HSCT的高危难治性白血病患者,采用7种含IDA的预处理方案。总结116例受者的植入情况。采用Kaplan-Meier曲线对2年总生存率(OS)、2年无病生存率(DFS)、累积复发率、复发病死率、移植相关病死率(TRM)、急性移植物抗宿主疾病(aGVHD)及慢性移植物抗宿主疾病(cGVHD)的累积发生率进行统计学分析。  结果  116例受者均成功植入。中位随访时间为28(7~70)个月,64例受者存活,2年OS为55.2%,2年DFS为51.7%,2年复发病死率23.3%,2年TRM为18.1%。116例受者中有72例发生aGVHD,aGVHD 2年累积发生率为62.1%,其中Ⅲ~Ⅳ度aGVHD 20例,2年累积发生率为17.2%。59例发生cGVHD,2年累积发生率为55.4%,其中广泛型cGVHD 2年累积发生率为14.7%。116例受者中有30例复发,2年累积复发率为25.9%。  结论  含IDA的预处理方案安全性和有效性均较高,可以作为高危难治性白血病患者移植预处理的有效方案。

     

  • 图  1  116例allo-HSCT受者aGVHD和cGVHD累积发生率

    Figure  1.  The cumulative incidence of aGVHD and cGVHD in 116 recipients after allo-HSCT

    图  2  不同预处理方案移植后2年总生存率和无病生存率

    Figure  2.  Two years overall survival and disease free survival after transplantation for different pretreatment schemes

    图  3  不同原发病的移植后2年总生存率和无病生存率

    Figure  3.  Two years overall survival and disease free survival of different original diseases after transplantation

  • [1] 中华医学会血液学分会白血病淋巴瘤学组.复发难治性急性髓系白血病中国诊疗指南(2017年版)[J].中华血液学杂志, 2017, 38(3):183-184. DOI: 10.3760/cma.j.issn.0253-2727.2017.03.002.

    Leukemia & Lymphoma Group in Branch of Hematology of Chinese Medical Association. The guidelines for diagnosis and treatment of acute myelogenous leukemia(relapse/refractory) in China (2017)[J]. Chin J Hematol, 2017, 38(3):183-184. DOI:10.3760/cma.j.issn. 0253-2727.2017.03.002.
    [2] KOBAYASHI H. Treatment of relapsed or refractory acute myeloid leukemia[J]. Rinsho Ketsueki, 2017, 58(10):1895-1904. DOI: 10.11406/rinketsu.58.1895.
    [3] SORROR ML. How I assess comorbidities before hematopoietic cell transplantation[J]. Blood, 2013, 121(15):2854-2863. DOI: 10.1182/blood-2012-09-455063.
    [4] MO XD, KONG J, ZHAO T, et al. Extramedullary relapse of acute leukemia after haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes[J]. Biol Blood Marrow Transplant, 2014, 20(12):2023-2028. DOI: 10.1016/j.bbmt.2014.08.023.
    [5] WANG J, ZHAO J, FEI X, et al. A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia[J]. Medicine (Baltimore), 2018, 97(17):e0228. DOI: 10.1097/MD.0000000000010228.
    [6] 中华医学会血液学分会干细胞应用学组.中国异基因造血干细胞移植治疗血液系统疾病专家共识(Ⅱ)——移植后白血病复发(2016年版)[J].中华血液学杂志, 2016, 37(10):846-851.DOI:10.3760/cma.j.issn. 0253-2727.2016.10.004.

    Stem Cell Application Group in Branch of Hematology of Chinese Medical Association. The consensus of allogeneic hematopoietic transplantation for hematological diseases in China (Ⅱ): post-transplant leukemia relapse (2016)[J]. Chin J Hematol, 2016, 37(10):846-851.DOI: 10.3760/cma.j.issn.0253-2727.2016.10.004.
    [7] 张利宁, 陈欣, 冯四洲, 等.异基因造血干细胞移植治疗复发难治急性髓系白血病研究进展[J].白血病·淋巴瘤, 2018, 27(7):444-448.DOI:10.3760/cma.j.issn. 1009-9921.2018.07.019.

    ZHANG LN, CHEN X, FENG SZ, et al. Progress of allogeneic hematopoietic stem cell transplantation in treatment of relapsed refractory acute myeloid leukemia[J]. J Leuk Lymphoma, 2018, 27(7):444-448.DOI: 10.3760/cma.j.issn.1009-9921.2018.07.019.
    [8] VAN DEN BRINK MR, PORTER DL, GIRALT S, et al. Relapse after allogeneic hematopoietic cell therapy[J]. Biol Blood Marrow Transplant, 2010, 16(Suppl 1):S138- S145. DOI: 10.1016/j.bbmt.2009.10.023.
    [9] ALYEA EP, KIM HT, HO V, et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome[J]. Biol Blood Marrow Transplant, 2006, 12(10):1047-1055. doi: 10.1016/j.bbmt.2006.06.003
    [10] 刘微, 李渊, 邱志祥, 等. FLAG序贯马利兰/环磷酰胺预处理方案对异基因造血干细胞移植治疗难治/复发性急性髓系白血病疗效影响的临床观察[J].中华内科杂志, 2018, 57(8):576-581.DOI:10.3760/cma.j.issn. 0578-1426.2018.08.008.

    LIU W, LI Y, QIU ZX, et al. Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide pretreatment regimen for refractory/relapsed acute myeloid leukemia[J]. Chin J Intern Med, 2018, 57(8):576-581.DOI: 10.3760/cma.j.issn.0578-1426.2018.08.008.
    [11] ZHANG R, LU X, WANG H, et al. Idarubicin-intensified hematopoietic cell transplantation improves relapse and survival of high-risk acute leukemia patients with minimal residual disease[J]. Biol Blood Marrow Transplant, 2019, 25(1):47-55. DOI: 10.1016/j.bbmt.2018.07.021.
    [12] 苏秀华, 姚剑峰, 张桂新, 等.异基因造血干细胞移植治疗难治/复发急性髓系白血病的疗效及预后因素分析[J].中华血液学杂志, 2017, 38(12):1024-1030. DOI: 10.3760/cma.j.issn.0253-2727.2017.12.004.

    SU XH, YAO JF, ZHANG GX, et al. Allogeneic hematopoietic stem cell transplantation for treatment of refractory and relapsed acute myeloid leukemia: outcomes and prognostic factors[J]. Chin J Hematol, 2017, 38(12):1024-1030. DOI:10.3760/cma.j.issn. 0253-2727.2017.12.004.
    [13] TANG W, FAN X, WANG L, et al. Busulfan and fludarabine conditioning regimen given at hematological nadir of cytoreduction fludarabine, cytarabine, and idarubicin chemotherapy in patients with refractory acute myeloid leukemia undergoing allogeneic stem cell transplantation: a single arm pilot consort study[J]. Medicine (Baltimore), 2015, 94(15):e706. DOI: 10.1097/MD.0000000000000706.
    [14] DOPPELHAMMER M, FRACCAROLI A, PREVALSEK D, et al. Comparable outcome after haploidentical and HLA-matched allogeneic stem cell transplantation for high-risk acute myeloid leukemia following sequential conditioning-a matched pair analysis[J]. Ann Hematol, 2019, 98(3):753-762. DOI: 10.1007/s00277-019-03593-2.
    [15] HOCHBERG J, ZAHLER S, GEYER MB, et al. The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia[J]. Bone Marrow Transplant, 2019, 54(2):226-235. DOI: 10.1038/s41409-018-0247-9.
    [16] HONG M, WU Q, HU C, et al. Idarubicin-intensified BUCY2 regimens may lower relapse rate and improve survival in patients undergoing allo-SCT for high-risk hematological malignancies: a retrospective analysis[J]. Bone Marrow Transplant, 2012, 47(2):196-202. DOI: 10.1038/bmt.2011.66.
    [17] FANG J, ZHANG R, WANG H, et al. Idarubicin-intensified BUCY2 conditioning regimen improved survival in high-risk acute myeloid, but not lymphocytic leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: a retrospective comparative study[J]. Leuk Res, 2016, 46:61-68. DOI: 10.1016/j.leukres.2016.04.014.
    [18] MARKS DI, KEBRIAEI P, STELLJES M, et al. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia[J]. Biol Blood Marrow Transplant, 2019, 25(9):1720-1729. DOI: 10.1016/j.bbmt. 2019.04.020.
    [19] KEBRIAEI P, STELLJE M, DEANGELO DJ, et al. Role of remission status and prior transplant in optimizing survival outcomes following allogeneic hematopoietic stem transplantation (HSCT) in patients who received inotuzumab ozogamicin for relapsed/refractory(R/R) acute lymphoblastic leukemia(ALL)[J]. Biol Blood Marrow Transplant, 2018, 24(3):S79-S80.DOI: 10.1016/j.bbmt.2017.12.622.
    [20] 孙于谦, 黄晓军.复发白血病异基因造血干细胞移植后疗效的改进策略[J].中华血液学杂志, 2017, 38(8):732-736. DOI: 10.3760/cma.j.issn.0253-2727.2017.08.018.

    SUN YX, HUANG XJ. Strategies for improving the outcomes of allogeneic stem cell transplantation in patients with relapsed acute leukemia[J]. Chin J Hematol, 2017, 38(8):732-736. DOI:10.3760/cma.j.issn.0253-2727. 2017.08.018.
    [21] BOSE P, VACHHANI P, CORTES JE. Treatment of relapsed/refractory acute myeloid leukemia[J]. Curr Treat Options Oncol, 2017, 18(3):17. DOI: 10.1007/s11864-017-0456-2.
    [22] CUI L, LIU Y, PANG Y, et al. Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia[J]. Cancer Gene Ther, 2020, 27(1/2):1-14. DOI: 10.1038/s41417-019-0119-5.
    [23] LOTFI K, ZACKRISSON AL, PETERSON C. Comparison of idarubicin and daunorubicin regarding intracellular uptake, induction of apoptosis, and resistance[J]. Cancer Lett, 2002, 178(2):141-149. doi: 10.1016/S0304-3835(01)00824-2
    [24] MUUS P, DONNELLY P, SCHATTENBERG A, et al. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent[J]. Semin Oncol, 1993, 20(6 Suppl 8):47-52. http://www.ncbi.nlm.nih.gov/pubmed/8290971
    [25] SPETH PA, MINDERMAN H, HAANEN C. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies[J]. Semin Oncol, 1989, 16(1 Suppl 2):2-9. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1177/104345429000700307
    [26] CASTAGNA L, SARINA B, BRAMANTI S, et al. Donor lymphocyte infusion after allogeneic stem cell transplantation[J]. Transfus Apher Sci, 2016, 54(3):345-355. DOI: 10.1016/j.transci.2016.05.011.
    [27] GOLDSMITH SR, SLADE M, DIPERSIO JF, et al. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy[J]. Bone Marrow Transplant, 2017, 52(12):1623-1628. DOI: 10.1038/bmt.2017.193.
    [28] ORTI G, BARBA P, FOX L, et al. Donor lymphocyte infusions in AML and MDS: enhancing the graft-versus-leukemia effect[J]. Exp Hematol, 2017, 48:1-11. DOI: 10.1016/j.exphem.2016.12.004.
  • 加载中
图(3)
计量
  • 文章访问数:  129
  • HTML全文浏览量:  79
  • PDF下载量:  6
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-12-15
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2020-03-15

目录

    /

    返回文章
    返回